Marco Meglio

James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.

Using a cohort of more than 2500 patients with MS on disease-modifying therapies, treatment initiation within the first 2 years of disease onset was more beneficial on patient-reported outcomes than 2-4 years postonset.

Short objective sleep duration was associated with weight regain and attenuated improvements in body composition one year after weight loss, independent of intervention allocation, age, and sex.

Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.

In the largest collected of PML DNA samples, the study identified 4 immune-linked, high effect size, rare variants for use in an iatrogenic PML risk genetic test.

AOC 1001, an agent consisting of a proprietary monoclonal antibody that binds to the transferrin receptor 1, was safe, tolerable, and showed significant reductions in DMPK, a disease-related mRNA.

Although the effects of the educational intervention weren’t seen at 3 months, investigators noticed significant differences relative to standard of care at 12 months.

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

In a phase 3 trial, NurOwn failed to meet its primary end point of change on ALSFRS-R; however, the therapy showed significant benefits in those with less severe forms of ALS.

Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.

Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.

High rates of treatment use were observed across all types of spinal muscular atrophy, with nusinersen, the first approved disease-modifying treatment, as the most commonly used.

Subsequent diagnosis of Parkinson disease was associated with a range of risk factors such as alcohol misuse and traumatic head injury, along with several other comorbidities and prodromal features.

Percentage of daily energy from ultraprocessed food was associated with cognitive decline in participants younger than 60 years, suggesting the importance of preventive interventions in middle-aged adults.

More than half of the patients who reported at least 1 trauma-related nightmare showed decreases after starting brief behavioral treatment.

After nearly a year of treatment with fenfluramine, more than half of patients with Lennox-Gastaut syndrome demonstrated at least a 50% reduction in drop seizure frequency.

The professor of dementia and executive dean of the Faculty of Health at the University of Plymouth provided perspective on the SYMBAD trial, and eliminating the use of mirtazapine and carbamazepine as medications to treat Alzheimer agitation.

Martina Bebin, MD, MPA, professor of neurology, University of Alabama at Birmingham Epilepsy Center, discussed Infantile Spasms Awareness Week, the strides made within the field, and the emphasis on early and accurate diagnosis.

After showing robust inhibition of biomarkers associated with integrated stress response, the eIF28 modulator will be assessed alongside several other potential agents in the HEALEY ALS Platform trial.

Over a 12-week treatment period, investigators found no significant differences in mean Cohen Mansfield Agitation Inventory scores between mirtazapine and placebo, with similar rates in adverse events.

Across 3 trials in patients with Alzheimer disease agitation, brexpiprazole doses of 2 or 3 mg/day was safe and showed a statistically significant improvement vs placebo in agitation.

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

The PDUFA date for SRP-9001, developed in partnership between Sarepta and Roche, is set for May 29, 2023. The BLA was submitted for accelerated approval.

In the pivotal phase 3 Clarity AD trial, lecanemab (Biogen) demonstrated significant impacts on primary and secondary end points, with additional promising results on biomarker analyses and safety.

In a post-hoc analysis of the ADVANCE trial, atogepant 30 and 60 mg produced significant improvements in outcomes on Migraine-Specific Quality of Life Questionnaire and Activity Impairment in Migraine-Diary domains.

Treatment with the investigational agent resulted in improvements in Alzheimer disease agitation, as well as significant delays in time to relapse and prevention of relapse.

The relative risk of epilepsy or seizures after COVID-19 infection, compared with influenza infection, was more marked amongst children and non-hospitalized individuals over the 6-month time horizon.

Nearly 40% of patients treated with CBT-I met the Athens Insomnia Score criteria for remission after 8 weeks of treatment compared with slightly above 10% of those on sham.

Peginterferon beta-1a, a pegylated form of interferon designed to maintain biologic effects in the body for longer periods, is being evaluated against CinnaGen’s interferon beta-1a formulation, CinnoVex.